drugset
drugset / Trial / NCT03393845

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845 ↗

Phase 2 Active not recruiting 47 enrolled Nancy Chan, MD Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Timeline

Start
2018-01-29
Primary completion
2023-08-04
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulvestrant Small molecule 500 mg Intramuscular
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

breast cancer